Guggenheim Keeps Buy Rating, Raises PT for ORIC Pharmaceuticals to $18.

Guggenheim Keeps Buy Rating, Raises PT for ORIC Pharmaceuticals to $18.

Guggenheim Securities has maintained its buy rating on ORIC Pharmaceuticals, Inc. (ORIC) stock while raising its price target to $18, according to a recent report. This move reflects the firm's positive outlook on the company's clinical programs and financial stability.

ORIC Pharmaceuticals reported strong Q2 2025 financial results, securing $244 million in financing, including a $125 million private placement and $119 million from ATM issuances. The company has extended its cash runway into the second half of 2028, providing substantial financial stability. The reported Phase 1b trial results for ORIC-944 in prostate cancer treatment, with a 59% PSA50 response rate and 24% PSA90 response rate, highlight the company's promising clinical pipeline.

Guggenheim's analysts noted that the strategic restructuring, including a 20% workforce reduction in discovery research, is a significant move towards a more focused clinical development company. The company is now prioritizing its two lead candidates: ORIC-944 for prostate cancer and enozertinib (ORIC-114) for NSCLC with various EGFR/HER2 mutations.

Despite recent stock fluctuations, including a sell signal from short and long-term moving averages, Guggenheim maintains a positive outlook. The stock's lower part of a strong rising trend in the short term may present a good buying opportunity, with an expected rise of 65.01% over the next three months, according to some analysts.

The analysts also mentioned that the stock is expected to hold a price between $15.32 and $21.37 at the end of this 3-month period. However, they cautioned that falling volume on higher prices could indicate potential changes in the near term.

References:
[1] https://stockinvest.us/stock/ORIC
[2] https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-reports-second-quarter-2025-financial-results-97aqz0u9ej5n.html